The innovative drug Yudige for myasthenia gravis, a severe disease, has been launched on the market in China.

Innovative biopharmaceutical company Ulpibio announced the official launch of its self-developed biologic drug "Rozelixizumab injection" in the domestic market. Rozelixizumab can simultaneously cover two types of patients, those positive for acetylcholine receptor antibodies and those positive for muscle-specific tyrosine kinase antibodies, bringing more treatment options for adult patients with generalized myasthenia gravis.